Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nimorazole SCHEMBL2555788 | 0.99 | POLB (0.44) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 | |
| Nimorazole SCHEMBL2556141 | 0.93 | PKM (0.43) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 | |
| Nimorazole SCHEMBL2552669 | 0.93 | MEN1 (0.40) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 | |
| Nimorazole SCHEMBL2555578 | 0.91 | PKM (0.44) | KMT2APOLBMEN1ALDH1A1MAPT | |
| Nimorazole SCHEMBL2549842 | 0.91 | GLA (0.46) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 | |
| Nimorazole SCHEMBL2555550 | 0.90 | KMT2A (0.38) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 | |
| Nimorazole SCHEMBL2558233 | 0.90 | KMT2A (0.38) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 | |
| Nimorazole SCHEMBL2555549 | 0.90 | KMT2A (0.38) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 | |
| Nimorazole SCHEMBL15570120 | 0.89 | MEN1 (0.38) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 | |
| Nimorazole SCHEMBL2552501 | 0.89 | GLA (0.43) | KMT2APOLBMEN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7213 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-12570704-B2 | Functionally modified maytansinoids and compositions and methods of use thereof | University of Georgie Research Foundation, Inc. (US) | 2026-03-10 | — | — | US | claimed |
| US-12544444-B2 | Administration of tailored feedstock to increase antibiotic susceptibility | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2026-02-10 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-4308181-B1 | SUTURES | UNIV BELFAST (GB) | 2025-11-19 | — | — | EP | claimed |
| US-12458694-B2 | Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody | ABCENTRA, LLC (US) | 2025-11-04 | — | — | US | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| US-20250268934-A1 | Compositions and Methods for the Treatment of Bacterial Vaginosis | WAYNE STATE UNIVERSITY (US) | 2025-08-28 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| WO-1995032720-A1 | COMPOSITION FOR TREATING GASTROINTESTINAL DISORDERS | HYBRID SCIENTIFIC PTY. LTD. (AU) | 1995-12-07 | — | — | WO | claimed |
| EP-0595890-A1 | ANTIMICROBIAL TREATMENT METHODS AND COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1994-05-11 | — | — | EP | claimed |
| US-5256684-A | Administering bismuth compound and antimicrobial agent | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-26 | — | — | US | claimed |
| EP-0543811-A1 | TOPICAL TREATMENT OF BLEPHARITIS | Bloom, Leonard (US) | 1993-06-02 | — | — | EP | claimed |
| WO-1993001818-A1 | ANTIMICROBIAL TREATMENT METHODS AND COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1993-02-04 | — | — | WO | claimed |
| EP-0206625-B1 | COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Marshall, Barry James, Dr. (US) | 1992-09-30 | — | — | EP | claimed |
| WO-1992003133-A1 | TOPICAL TREATMENT OF BLEPHARITIS | BLOOM, LEONARD (US) | 1992-03-05 | — | — | WO | claimed |
| EP-0462631-A1 | Methods and compositions for the treatment of gastrointestinal disorders | Marshall, Barry James, Dr. (US) | 1991-12-27 | — | — | EP | claimed |
| US-4957918-A | Topical treatment of blepharitis | Bloom, Leonard (US) | 1990-09-18 | — | — | US | claimed |
| US-4218449-A | NITROIMIDAZOLE COMPOUNDS | Simoons, John R. A. (US) | 1980-08-19 | — | — | US | claimed |